Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 3/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22052776 | 0.81 | HRH3 (0.36) | KMT2APKMDPP4HRH3MGLL | |
| SCHEMBL22052773 | 0.79 | KMT2A (0.33) | KMT2ATSHRMEN1MAPTNPSR1 | |
| SCHEMBL21740219 | 0.77 | KMT2A (0.38) | KMT2ATSHRMEN1MAPTNPSR1 | |
| SCHEMBL21740228 | 0.75 | PIM1 (0.37) | KMT2ATSHRMEN1MAPTNPSR1 | |
| SCHEMBL21740217 | 0.74 | ALDH1A1 (0.53) | KMT2ATSHRMAPTPKMALDH1A1 | |
| SCHEMBL21739728 | 0.74 | HRH4 (0.43) | KMT2AALDH1A1 | |
| SCHEMBL21739718 | 0.73 | JAK1 (0.35) | KMT2ATSHRMEN1MAPTNPSR1 | |
| SCHEMBL21739173 | 0.73 | ALDH1A1 (0.55) | KMT2AMEN1MAPTHRH3ALDH1A1 | |
| SCHEMBL21739722 | 0.73 | ALDH1A1 (0.37) | KMT2ATSHRMEN1MAPTNPSR1 | |
| SCHEMBL21739194 | 0.71 | RIPK1 (0.48) | KMT2AMEN1MAPTDPP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. | 2023-02-16 | — | — | US | disclosed |
| WO-2020112872-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | NSD1, NSD3, EHMT1 | KMT2A 33/4885TSHR 4520/4885MEN1 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.